Nabi Biopharmaceuticals Announces Second Quarter 2007 Financi...(ing relapse: -- Further analysis of t...),Health

-- Further analysis of the six-month data has enabled Nabi to determine

both the therapeutic threshold at which quitting is first observed as

well as the target upper limit of antibody concentration.

-- In the nine-month data, NicVAX continues to demonstrate efficacy in

support of long-term smoking abstinence - the most effective NicVAX

dose regimen was 400 micrograms delivered in five injections over six

months. A statistically significant difference was seen when this

treated group was compared to placebo over time for the full Intent to

Treat (ITT) population:

-- Fixed 4-Week: NicVAX=24% (n=12/51); Placebo=14% (n=14/100) - p=0.14

-- Fixed 8-Week: NicVAX=20% (n=10/51); Placebo=13% (n=13/100) - p=0.29

-- Fixed 20-Week: NicVAX=20% (n=10/51); Placebo= 4% (n=4/100) -

p=0.0018

-- Fixed 34-Week: NicVAX=18% (n=9/51); Placebo=4% (n=4/100) - p=0.0047

-- To date, NicVAX continues its attractive safety trends with a

favorable adverse events profile comparable between placebo and each

dose group.

Recent Accomplishments

April:

-- Executed a definitive agreement to sell Aloprim(TM) (allopurinol

sodium) for Injection to Bioniche Teoranta for $3.7 million; the sale

was completed in May

May:

-- Established "proof of concept" for NicVAX in its Phase 2b clinical

trial, which met its primary endpoint of eight weeks of continuous

smoking abstinence between weeks 19-26

-- Participated in the Phacilitate Vaccine Forum Munich 2007, where

NicVAX principal investigator Dr. Dorothy Hatsukami, Forster Family

Professor in Cancer Prevention and Professor of Psychiatry at the

University of Minnesota Tobacco Use Research Center, discussed NicVAX

Phase 2b data in greater detail

June:

-- Formed the Nabi Bio
'/>"/>

SOURCE Nabi Biopharmaceuticals Copyright©2007 PR Newswire.

0 GOOD